Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates
Executive Summary
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
You may also be interested in...
Finance Watch: Nkarta, Passage Bio Raise Venture Capital Mega-Rounds
Private Company Edition: Nkarta, Passage Bio and Achilles kicked off September with VC deals totaling more than $100m each. Also, Repare raised $82.5m and SutroVax won CARB-X cash.
Poziotinib Shows Promise In EGFR Exon 20 Mutant NSCLC
Hanmi and Spectrum's novel oral pan-HER inhibitor poziotinib shows promising interim results in Phase II study in NSCLC patients with EGFR exon 20 insertion mutations, an unmet need.
Janssen Expanding Its Disease Interception Efforts
Through a series of research agreements, J&J arm is seeking to create new business models teaming a single internal expert with a host of external researchers in six priority therapeutic areas.
Need a specific report? 1000+ reports available
Buy Reports